Cambridge Cognition Holdings plc (LON: COG), which develops and markets neuroscience technology to assess brain health, announced it has won a significant new clinical trial contract. Stephen Powell, CEO of Cambridge Cognition joins Directorstalk to discuss the contract. Stephen provides some further details on the background to winning the eCOA contract, how the new partner will be using this technology, how increasing the capabilities of the CANTAB connect platform is benefiting the company and what progress to expect over the coming months for outcome assessment based contacts.
Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The company’s software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early, and reduce global R&D and healthcare costs.